Eli Lilly's stock surged over 50% YTD, attracting investors despite trading at over 100-times earnings, leading to valuation concerns.
Eli Lilly, a top pharma stock, dominates the GLP-1 weight loss market, positioning for sustained growth, despite competition and investment challenges.
Collection
[
|
...
]